Atherosclerosis Clinical Trial
— CAC-TRAITOfficial title:
Detection of Coronary Artery Calcifications by Whole Blood Transcriptome Analyzed by Artificial InTelligence Algorithms. (CAC-TRAIT Study)
NCT number | NCT05619042 |
Other study ID # | CCT2 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | November 7, 2022 |
Est. completion date | January 24, 2024 |
Verified date | March 2024 |
Source | MultiplAI Health Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The goal of this observational study is to determine the diagnostic accuracy of peripheral whole blood transcriptomes analyzed by an artificial intelligence algorithm to detect the presence and extent of coronary calcification in individuals without a history of known cardiovascular disease. The main question it aims to answer is: 1. Will the proposed method predict the presence and extent of coronary artery calcification from the peripheral whole-blood transcriptomes?
Status | Completed |
Enrollment | 800 |
Est. completion date | January 24, 2024 |
Est. primary completion date | January 24, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 30 Years to 75 Years |
Eligibility | Inclusion Criteria: - Men and women between 30 and 75 years attending the institution for a non-contrast cardiac CT scan (coronary calcium score) either by medical indication or voluntary for cardiovascular risk assessment. - Signature of the informed consent form Exclusion Criteria: - Previously known chronic renal or hepatic insufficiency. - Active chronic lung disease, defined as exacerbated asthma, exacerbated chronic obstructive pulmonary disease (COPD), or pulmonary fibrosis. - Active and/or previous cardiovascular disease, defined as previous acute myocardial infarction, stable or unstable angina, cerebrovascular accident, history of vascular interventions (coronary or another territory), heart failure, severe cardiomyopathies, or valvulopathies. - Uncontrolled hyper or hypothyroidism. - Suprarenal insufficiency. - Previous surgeries in the last 3 months. - Severe trauma in the last 6 months, defined as one that involved bone fractures and/or surgical interventions. - Known active cancer disease or under treatment (acute or preventive), or history of cancer disease without criteria for a cure. - Known autoimmune disease active or in treatment. - Ongoing pregnancy, postpartum period of fewer than 12 months, or breastfeeding. - Other serious illnesses with an estimated life expectancy of fewer than 12 months (according to the investigators). - Temperature greater than 37.5°C recorded by a thermometer or any acute infection caused by viruses or bacteria confirmed by a health professional in the previous 30 days. - Pathologies under immunosuppressive treatment |
Country | Name | City | State |
---|---|---|---|
Argentina | Clinica Sagrada Familia | Ciudad Autonoma de Buenos Aires |
Lead Sponsor | Collaborator |
---|---|
Santiago Gabriel Miriuka | Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia |
Argentina,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Coronary artery calcium score | Coronary artery calcium (CAC) score (Agatston units) stratified with increasing risk according to the Society of Cardiovascular Computed Tomography Guidelines as CAC=0; CAC 1-99; CAC 100-299; and CAC=300. | At baseline (cross-sectional assessment) | |
Secondary | Coronary artery calcium score | Percentile Agatston score: according to age and sex with a increasing risk ranging from 1 to 99 th percentile. | At baseline (cross-sectional assessment) | |
Secondary | Coronary artery calcium score (number of segments) | Number of segments with coronary calcifications ranging from 0 to 17 segments. | At baseline (cross-sectional assessment) | |
Secondary | Aortic valve calcium | Aortic valve calcification score (Agatston units) as a continuous variable with increasing risk and without preestablished thresholds | At baseline (cross-sectional assessment) | |
Secondary | Thoracic aorta calcium | Thoracic aorta calcification score (Agatston units) as a continuous variable with increasing risk and without preestablished thresholds | At baseline (cross-sectional assessment) | |
Secondary | Epicardial adipose tissue (volume) | cm2/m2 | At baseline (cross-sectional assessment) | |
Secondary | Epicardial adipose tissue (density) | density, Q1-Q4: quartiles percentage | At baseline (cross-sectional assessment) | |
Secondary | Fatty liver | liver attenuation <48 Hounsfield units | At baseline (cross-sectional assessment) | |
Secondary | Neutrophil to lymphocyte ratio | hematological parameter for systemic inflammation and stress | At baseline (cross-sectional assessment) | |
Secondary | High-sensitive C reactive protein (CRP) | mg/dl | At baseline (cross-sectional assessment) | |
Secondary | Repolarization abnormalities | Number of participants with repolarization abnormalities on a 12-lead ECG, defined as ST segment depression or pathological T wave inversion. | At baseline (cross-sectional assessment) | |
Secondary | Left ventricular hypertrophy | Number of participants with left ventricular hypertrophy on a 12-lead ECG, defined by positive Sokolow-Lyon or Cornell criteria. | At baseline (cross-sectional assessment) | |
Secondary | Intraventricular conduction abnormalities | Number of participants with intraventricular conduction abnormalities on a 12-lead ECG, stratified by the presence of left bundle branch
block; right bundle branch block and left posterior fascicular block; right bundle branch block and left anterior fascicular block or right bundle branch block; or left anterior fascicular block. |
At baseline (cross-sectional assessment) | |
Secondary | Percent electron density relative to water (%EDW) | percent electron density relative to water, available for direct evaluation with dedicated software in all scans acquired using a dual-layer spectral CT scanner). | At baseline (cross-sectional assessment) | |
Secondary | Death | Number of participants with report of death from any cause | year 1 through 5 | |
Secondary | Acute ischemic syndrome | Number of participants with non fatal diagnosis of acute myocardial infarction or unstable angina | year 1 through 5 | |
Secondary | Heart failure | Number of participants with non fatal new diagnosis of heart failure with preserved or impaired ventricular function | year 1 through 5 | |
Secondary | Vascular revascularization | Number of participants with performance of myocardial revascularization surgery, coronary angioplasty or peripheral vascular angioplasty | year 1 through 5 | |
Secondary | cerebrovascular event | Number of participants with non fatal diagnosis of cerebrovascular accident ("stroke") or transient ischemic attack | year 1 through 5 | |
Secondary | Cancer | Number of participants with new diagnosis of any type of cancer | year 1 through 5 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05052918 -
The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes
|
N/A | |
Recruiting |
NCT04511234 -
Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease
|
N/A | |
Completed |
NCT05906797 -
Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Periodontitis.
|
N/A | |
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Suspended |
NCT02932176 -
Machine Learning for Handheld Vascular Studies
|
||
Recruiting |
NCT05158257 -
Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity
|
N/A | |
Completed |
NCT01212900 -
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
|
Phase 4 | |
Completed |
NCT03697382 -
Effect of Daily Steps on Fat Metabolism
|
N/A | |
Recruiting |
NCT06230406 -
T-Mem GEne in Atherosclerosis
|
||
Completed |
NCT03654313 -
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
|
Phase 1 | |
Completed |
NCT00382564 -
Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease
|
N/A | |
Recruiting |
NCT02894931 -
Effects of Dietary Interventions on Serum and Macrophage Atherogenicity
|
N/A | |
Not yet recruiting |
NCT02578355 -
National Plaque Registry and Database
|
N/A | |
Completed |
NCT02998918 -
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL
|
N/A | |
Recruiting |
NCT02265250 -
Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
|
||
Completed |
NCT03393377 -
Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination
|
N/A | |
Completed |
NCT02224339 -
New Technologies to Determine Carotid Plaque Vulnerability
|
||
Completed |
NCT02268513 -
Mediators of Atherosclerosis in South Asians Living in America (MASALA) Social Network Study
|
||
Not yet recruiting |
NCT01923012 -
Phase II Randomized Placebo-controlled Study With Vitamin K2 in Asymptomatic Calcified Carotid Stenosis
|
Phase 2 | |
Completed |
NCT02377310 -
Pd/Pa vs iFR™ in an Unselected Population Referred for Invasive Angiography
|
N/A |